Original Source

Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer

JAMA Network Open

Volume: 5: e220145 Issue: 2

22 FEB 2022

Van Blarigan, E. L., Ou, F. S., Bainter, T. M., Fuchs, C. S., Niedzwiecki, D., Zhang, S., et. al.

1

Yes

From the source: "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology); U10CA032291, U10CA041287, U10CA045808, U10CA077651, U10CA138561, U10CA180791, and U10CA180820 (to ECOG-ACRIN Cancer Research Group); U10CA180836, U10CA180867, and U10CA180888 (to SWOG Cancer Research Network); UG1CA189858 (to the Southeast Clinical Oncology Research Consortium, Inc); K07CA197077 (to Dr Van Blarigan); R01CA118553 (to Dr Fuchs); and R35CA197735 (to Dr Ogino). Dr Meyerhardt’s research is supported by the Douglas Gray Woodruff Chair fund, the Guo Shu Shi Fund, Anonymous Family Fund for Innovations in Colorectal Cancer, Project P fund, and the George Stone Family Foundation."

From the source: "Dr. Benson reported serving as an advisor and consultant to Novartis, Merck Sharpe & Dohme, BMS, Harborside, Guardant, NCCN, PrECOG, Pfizer, Dava Onc, Patient Resource, Research to Practice, Springer, Bayer, Genentech, Array BioPharma, Bristol-Myers Squibb, Samsung Bioepis, HalioDx, Abbvie, Janssen Oncology, Natera, Apexigen, Artemida, Xencor, Therabionic, Mirati, Boston Scientific, and Hutchmed; receiving research funding from Celegene, Infinity Pharmaceuticals, Merck Sharp and Dohme, Taiho Pharmaceuticals, Rafael Pharmaceuticals, Medimmune/AstraZeneca, Xencor, LSK, AVBCC, Array, Amgen, ITM Solucin GmbH, Elevar Therapeutics, Inc, ST Pharm Co, Ltd, and Mirati Therapeutics; and serving on the data safety and monitoring committees for Bristol-Myers Squibb, PreECOG, Astellas Pharma, Amgen, ECOG-ACRIN, SynCore, and Tyme, Inc (Iqvia). Dr Sanoff reported receiving institutional research funding from Bayer. Dr Meyerhardt reported receiving institutional research funding from Boston Biomedical, serving as an advisor and consultant to COTA Healthcare and an ad hoc advisory board for Merck, and serving on a grant review panel for the National Comprehensive Cancer Network funded by Taiho Pharmaceutical. No other disclosures were reported."

Posted on

Summary

Summary is currently unavailable. Please see the abstract below.

Importance: The American Cancer Society and American Institute for Cancer Research recommend that cancer survivors limit intake of red and processed meats. This recommendation is based on consistent associations between red and processed meat intake and cancer risk, particularly risk of colorectal cancer, but fewer data are available on red and processed meat intake after cancer diagnosis.

Objectives: To examine whether intake of unprocessed red meat or processed meat is associated with risk of cancer recurrence or mortality in patients with colon cancer.

Design, Setting, and Participants: This prospective cohort study used data from participants with stage III colon cancer enrolled in the Cancer and Leukemia Group B (CALGB 89803/Alliance) trial between 1999 and 2001. The clinical database for this analysis was frozen on November 9, 2009; the current data analyses were finalized in December 2021.

Exposures: Quartiles of unprocessed red meat and processed meat intake assessed using a validated food frequency questionnaire during and 6 months after chemotherapy.

Main Outcomes and Measures: Hazard ratios (HRs) and 95% CIs for risk of cancer recurrence or death and all-cause mortality.

Results: This study was conducted among 1011 patients with stage III colon cancer. The median (IQR) age at enrollment was 60 (51-69) years, 442 patients (44%) were women, and 899 patients (89%) were White. Over a median (IQR) follow-up period of 6.6 (1.9-7.5) years, we observed 305 deaths and 81 recurrences without death during follow-up (386 events combined). Intake of unprocessed red meat or processed meat after colon cancer diagnosis was not associated with risk of recurrence or mortality. The multivariable HRs comparing the highest vs lowest quartiles for cancer recurrence or death were 0.84 (95% CI, 0.58-1.23) for unprocessed red meat and 1.05 (95% CI, 0.75-1.47) for processed meat. For all-cause mortality, the corresponding HRs were 0.71 (95% CI, 0.47-1.07) for unprocessed red meat and 1.04 (95% CI, 0.72-1.51) for processed meat.

Conclusions and Relevance: In this cohort study, postdiagnosis intake of unprocessed red meat or processed meat was not associated with risk of recurrence or death among patients with stage III colon cancer.

This article is licensed under a Creative Commons Attribution International License, http://creativecommons.org/licenses/